The current situation: Erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer

Oncologist

Volumn 10, Issue 7, 2005, Pages 467-470

  Comis, Robert L ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Epidermal growth factor receptor; Erlotinib; Gefitinib; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; NOTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 24644445982     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-7-467     Document Type: Note

References (22)

1. Shepherd FA, Pereira J, Ciuleanu TE et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. J Clin Oncol 2004;22(suppl 14):12.
2. U.S. Food and Drug Administration. IRESSA® (ZD1839, gefitinib) Tablets. Oncologic Drugs Advisory Committee (ODAC) Meeting Briefing Document, March 4, 2005. Available at http://www.fda.gov/ohrms/ dockets/ac/05/briefing/ 2005-4095B2_01_01-AstraZeneca-Iressa.pdf. Accessed July 12, 2005.
3. AstraZeneca Pharmaceuticals. Gefitinib (Iressa™) Marketing Authorisation Application Withdrawn in EU. Press Release, January 4, 2005. Available at http://www.astrazeneca.com/pressrelease/4442.aspx. Accessed July 12, 2005.
4. Thatcher N, Chang A, Parikh P et al. Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Proc Am Assoc Cancer Res 2005; Late Breaking Session: LB-6.
5. Cohen M, Johnson JR, Chen YF et al. FDA drug approval summary: erlotinib (Tarceva®) Tablets. The Oncologist 2005;10:461-466.
6. Hamilton M, Wolf JL, Zborowski D et al. Tarceva™ (erlotinib) exposure/effects (EE) analysis from a phase III study in advanced NSCLC: effect of smoking on the PK of erlotinib. Proc Am Assoc Cancer Res 2005;46:56.
7. Clark GM, Zborowski D, Santabarbara P et al. Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression. J Clin Oncol 2005;23(suppl 16):628.
8. Kosaka T, Yatabe Y, Endoh H et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
9. Genentech, Inc. Tarceva® erlotinib tablets. Package Insert. Available at http://www.tarceva.com/tarceva/professional/prescribing/ PI.jsp#dosage. Accessed July 12, 2005.
10. Mita CA, Schwartz G, Mita MM et al. A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005;23(suppl 16):203.
11. Sainsbury JR, Farndon JR, Needham GK et al. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987;329:1398-1402.
12. Fujino S, Enokibori T, Tezuka N et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996;32A(12):2070-2074.
13. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
14. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
15. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
16. Hecht JR, Patnaik A, Malik I et al. A BX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. J Clin Oncol 2004;22(suppl 14):248.
17. Tsao MS, Sakurada A, Lorimer I et al. Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. J Clin Oncol 2005;23(suppl 16):622.
18. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
19. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
20. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
21. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005;23(suppl 16):2.
22. Tsao AS, Herbst R, Sandler A et al. Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: correlation of treatment response with mutations of the EGFR tyrosine kinase gene. J Clin Oncol 2005;23(suppl 16):643.